Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Dividends Paid - Common (2019)

BridgeBio Pharma (BBIO) has disclosed Dividends Paid - Common for 1 consecutive years, with $54.0 million as the latest value for Q3 2019.

  • Quarterly Dividends Paid - Common changed N/A to $54.0 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $55.0 million through Dec 2019, changed N/A year-over-year, with the annual reading at $5.0 million for FY2020, 90.91% down from the prior year.
  • Dividends Paid - Common hit $54.0 million in Q3 2019 for BridgeBio Pharma, up from $997000.0 in the prior quarter.
  • In the past five years, Dividends Paid - Common ranged from a high of $54.0 million in Q3 2019 to a low of $997000.0 in Q1 2019.